Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Alexei Basnakian

Alexei Basnakian

University of Arkansas for Medical Sciences, USA

Title: DNase/endonuclease network: a new target for mitigation of acute nephrotoxicity

Biography

Biography: Alexei Basnakian

Abstract

Statement of the Problem: Deoxyribonucleases (DNases) universally induce irreversible cell death by fragmenting DNA in response to cell injury. All of the nine known cell death DNases are endonucleases. Despite that most of the DNase activity is used after cell death, a genetic inactivation of DNases provide protection of cells and tissues against DNA breaks induced by cytotoxic stimuli, and partially protect against tissue injury. Therefore, DNases act before the point-of-no-return in cell death, and can be potentially used as therapeutic targets for tissue protection against injury. Our studies identified two DNases, DNase I and EndoG, as being responsible for tubular epithelial toxicity during acute kidney injury induced by cisplatin, rhabdomyolysis or ischemia. However, inhibitors of DNases are not available. The purpose of this study was to identify DNase inhibitors, which might be used for mitigation of acute kidney injury.

Methodology & Theoretical Orientation: To identify DNase inhibitors, we have developed a high-throughput screening assay based on a proprietary fluorescent probe.

Findings: This assay allowed the identification of several new inhibitors of deoxyribonuclease I (DNase I), which were also active against two other DNases, endonucleases G (EndoG) and deoxyribonuclease II (DNase II). The DNase inhibitors were able to significantly protect kidney tubular epithelial cells in vitro and mouse kidneys in vivo against acute kidney toxicity induced by cisplatin, glycerol (rhabdomyolysis), or renal ischemia-reperfusion. The inhibitors showed no toxicity in vivo at 5x therapeutic doses.

Conclusion & Significance: DNases can be used as a therapeutic target for mitigation of toxic or hypoxic acute kidney injury. The identified DNase inhibitors or similar compounds have a great potential for tissue protection against toxic kidney failure. Considering that DNases are expressed and responsible for cell death in all tested cells, tissues and animal models, it is likely that the same compounds may be used for universal tissue protection against various injuries.